Home > Insider Trading > Filing (0001140361-10-024830)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1184149	W Jonathan Ayers	One Idexx Drive Westbrook ME 04092	Chairman, President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-06-07	50,000	$12.60	236,699	No	4	M	Direct
Common Stock	Disposition	2010-06-07	28,500	$61.29	208,199	No	4	S	Direct
Common Stock	Disposition	2010-06-07	12,097	$62.06	196,102	No	4	S	Direct
Common Stock	Disposition	2010-06-07	128	$62.98	195,974	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2010-06-07	50,000	$0.00	50,000	$12.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
590,320		2012-01-28	No	4	M	Direct

Footnotes

The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/3/2009.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $60.75 to $61.74, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $61.79 to $62.66, inclusive.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $62.80 to $63.03, inclusive.
Grant of option to buy shares of common stock exercisable in five equal annual increments beginning on the first anniversary date (1/28/2003) of the grant.